Introduction {#Sec1}
============

The beneficial effect of intraocular pressure (IOP) lowering treatments to reduce glaucoma progression has been demonstrated by a number of multicenter, randomized studies \[[@CR1]--[@CR4]\]. On the other hand, more recent studies have also shown the detrimental effects of medical treatments for glaucoma on the ocular surface \[[@CR5]--[@CR11]\]. It has been shown that prostaglandin analogs have inflammatory effects \[[@CR5]--[@CR9], [@CR11]\], yet the vast majority of side effects are due to preservatives, in particular benzalkonium chloride (BAK), which is the most toxic and most used of ophthalmic preservatives \[[@CR5]--[@CR11]\]. BAK effects are dose dependent \[[@CR7]--[@CR12]\], and this is relevant considering that most glaucoma patients receive more than one IOP-lowering treatment \[[@CR4]\]. Chronic BAK exposure is also associated with reduced efficacy of glaucoma surgery \[[@CR13]\]. As a consequence, preservative-free treatments are preferable for glaucoma, as for all chronic eye diseases \[[@CR14]\].

Confocal microscopy is a recent technique which enables ophthalmologists to detect subtle inflammatory and toxic changes of the ocular surface \[[@CR15]\]. By means of confocal microscopy, BAK has been shown to reduce the density of conjunctival goblet cells \[[@CR16], [@CR17]\], of conjunctival and corneal epithelial cells \[[@CR17]\], and to deteriorate the normal characteristics of corneal nerves \[[@CR18]--[@CR20]\].

Still, timing of occurrence of ocular surface changes when starting IOP-lowering treatments is an unexplored issue. Tafluprost is the most recent unpreserved prostaglandin analog introduced in clinical practice and it is characterized by the absence of BAK.

To the best of the author's knowledge, this is the first study to investigate and compare, from both clinical and confocal viewpoints, the effects of preserved and unpreserved prostaglandin analogs in newly diagnosed glaucoma patients with normal ocular surface.

Materials and Methods {#Sec2}
=====================

A randomized, masked, prospective study was carried out to test the primary hypothesis that treatment with preserved prostaglandins induces confocal changes of the cornea (both stromal inflammation and toxic damage to the sub-basal nerves) and that these anatomical changes would induce clinical changes, as detected during a general ophthalmic examination.

Inclusion Criteria {#Sec3}
------------------

Inclusion criteria for the present study were: diagnosis of ocular hypertension (OH), primary open-angle glaucoma (POAG), pseudoexfoliative glaucoma or normal tension glaucoma, according to the definitions of the European Glaucoma Society Guidelines \[[@CR21]\]; no previous treatments to reduce IOP and no treatment with any BAK-preserved eye drop for at least 6 months before the study; no fluorescein staining at baseline and no observable signs of ocular surface disease.

Exclusion Criteria {#Sec4}
------------------

Exclusion criteria for the present study were: unwillingness to sign informed consent; aged \<18 years; any ocular condition that was of safety concern or interfering with the study results; any ocular condition requiring the use of eye drops during follow-up (i.e., dry eye); closed/barely open anterior chamber angles or history of acute angle closure; ocular surgery or argon laser trabeculoplasty within the last year; ocular inflammation/infection occurring within 3 months prior to pre-trial visit; presence of the following ocular conditions: dry eye, moderate--severe blepharitis, Rosacea, Sjogren syndrome, pterygium or use of contact lens(es); hypersensitivity to BAK or to any other component of the trial drug solutions; any corneal pathology; diabetes at any stage; other abnormal condition or symptom preventing the patient from entering the trial (need for more than 1 IOP-lowering treatment), according to the investigator's judgment; refractive surgery patients; women who were pregnant, of childbearing potential and not using adequate contraception or nursing; inability to adhere to treatment/visit plan.

Clinical Plan {#Sec5}
-------------

The study protocol comprised 5 visits (performed at Eye Clinic of San Paolo Hospital, Milan, Italy): Baseline, Month 3, Month 6, Month 9 and Month 12.

At baseline, a clinical evaluator performed a complete ophthalmologic evaluation to confirm diagnosis. The following examinations were done in the following sequence: anterior segment examination, Schirmer's test and break-up time test. Thereafter, a confocal evaluator performed confocal microscopy of the central cornea. Finally, contact measurements were carried out in the following order: IOP, pachymetry and gonioscopy. A 15-min interval between two consecutive tests was observed.

A study coordinator recorded medical history and then randomized patients into two groups: one group to receive unpreserved (tafluprost 0.0015%, Saflutan^®^, Santen Pharmaceutical, Osaka, Japan) and one group to receive preserved prostaglandins (latanoprost 0.005% + BAK 0.02%, Xalatan^®^, Pfizer S.r.L., Latina, Italy) once daily to both eyes (randomization of 1:1, by means of a list of random numbers). Being patients treated to both eyes, a control group was not available. During the study, patients were instructed not to use any other topical treatment other than the study medication. The confocal and the clinical investigators were masked to treatment.

Confocal and clinical examinations, as described above, were repeated at months 3, 6, 9 and 12.

Adherence to treatment, medical history, and side effects were checked by study coordinator at follow-up visits. Adverse effects were recorded. Symptoms were evaluated by means of comparison of ophthalmic medications for tolerability (COMTOL) questionnaire \[[@CR22]\].

Corneal Confocal Biomicroscopy {#Sec6}
------------------------------

The second version of Heidelberg Retina Tomograph (Heidelberg Engineering, Heidelberg, Germany) is endowed with a lens system called the \[Rostock Cornea Module (RCM)\], and allows an in vivo confocal study of the ocular surface. The laser source used in the RCM is a diode laser with a wavelength of 670 nm. The acquired two-dimensional images have a definition of 384 × 384 pixels over an area of 400 µm × 400 µm with lateral digital resolution of 1 µm/pixel and a depth resolution of 2 µm/pixel.

After administration of one drop of 0.4% oxybuprocaine and one drop of a lubricant gel (0.2% carbomer), the patient was asked to fixate on a small, bright, red light as the examination was performed in the contralateral eye. Correct alignment and contact with the cornea were monitored using the images captured by a camera tangential to the eye. The distance from the cornea to the microscope was kept stable using a single-use contact element in sterile packaging, (TomoCap, Heidelberg Engineering, Heidelberg, Germany). The examination took about 7 min per eye; 5 images of each cornea layer and of the sub-basal layer were collected, both in central area. The highest resolution images taken of the different layers were considered for the analysis.

Test--retest variability of confocal microscopy of the central cornea was tested at the beginning of the study using the following method. 5 eyes of 5 volunteers were tested 3 times each: twice during the same day (at 9 a.m. and at 11 a.m.) and once the day after (at 9 a.m.). The confocal operator evaluated these images and found an agreement of 80% or more for all parameters.

Sample Size Calculation {#Sec7}
-----------------------

Given the paucity of information available on the effects of treatments with BAK-free prostaglandin on the ocular surface studied by confocal imaging, sample size calculation for this pilot study may be imprecise. The outcome of the study was corneal inflammation at confocal microscopy (defined as activation of anterior stroma, changes of nerve morphology, increase of dendritic cells). If a worth-detecting difference of 40% between the two groups is assumed, the presence of subclinical inflammation in 30% of normal cases, a one-tailed distribution in favor of the BAK-free arm of the study, *α* = 0.05, *β* = 0.2, a sample of 20 eyes would be necessary \[[@CR20], [@CR23], [@CR24]\]. It was decided to overpower the study including all treated eyes (a control group was absent in any case, being patients treated to both eyes), and this gave a study power of nearly 90%.

Statistical Analysis {#Sec8}
--------------------

All available data were analyzed (i.e., all eyes receiving study product were analyzed). The dataset was analyzed by means of linear and generalized, mixed-effect models of analysis of variance (ANOVA), with a post hoc test. In case of multiple comparisons, *t* test and Chi-square tests with Bonferroni--Holm correction were used. R open-access software was used (version 3.1.3, R foundation for statistical computing, Vienna, Austria).

Compliance with Ethics {#Sec9}
----------------------

This present study was performed at the Eye Clinic, Department of Medicine, Surgery and Odontoiatry, San Paolo Hospital, University of Milan, Italy.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (University of Milan, Italy) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

Results {#Sec10}
=======

Forty consecutive patients with new diagnosis of glaucoma or ocular hypertension were enrolled between January and July 2013. The study included 32 and 35 eyes in the tafluprost and latanoprost groups, respectively. Demographic characteristics of the study population and main study results are given in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. The two groups had similar age and ocular surface and confocal findings at baseline (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). At the beginning of the study, activation of anterior stromal keratocytes was present in 40% of total patients (28% and 50% of subjects in latanoprost and tafluprost groups, respectively, *p* = 0.08); branching pattern was present in about 85% of patients, and beading in 75% of cases.Table 1Demographic and main ocular features of the study populationTafluprostLatanoprostTotalNumber of patients202040Number of eyes323567Age years (SD)68.5 ± 12.363.4 ± 14.465.9 ± 13.5Sex f/m7/108/1015/20Refraction0.98 ± 0.281.1 ± 0.281.03 ± 0.28IOP mmHg (SD)18.5 ± 4.018.5 ± 5.518.5 ± 5.0*IOP* intraocular pressure, *f/m* female/male, *SD* standard deviationTable 2Clinical data of the study populationBaselineMonth 3Month 6Month 9Month 12LatanoprostTafluprostLatanoprostTafluprostLatanoprostTafluprostLatanoprostTafluprostLatanoprostTafluprostSchirmer's test, mm mean ± SD (CI 95%)16.6 ± 10.1 (13.3;19.9)16.8 ± 8.5 (13.8;19.7)15.9 ± 9.6 (12.7;19.1)15.7 ± 10.7 (12;19.4)18.1 ± 8.9 (15.1;21)14.3 ± 10.4 (10.6;17.9)17.8 ± 8.8 (14.9;20.7)17.8 ± 10.3 (14.2;21.4)18 ± 10.1 (14.6;21.4)16.9 ± 10.9 (13.1;20.7)Break-up time, s mean ± SD (CI 95%)7.7 ± 4.2 (6.3;9.1)7.7 ± 3.1 (6.6;8.8)7.1 ± 2.8 (6.2;8)7.6 ± 2.6 (7;8.8)7.5 ± 2.5 (6.6;8.3)7.8 ± 2.9 (6.8;8.7)7.1 ± 2.9 (7.1;9)7.1 ± 2.7 (7.1;9)7.0 ± 3.7 (8.7;11.2)7.3 ± 3.1 (7.1;9.2)Intraocular pressure mmHg mean ± SD (CI 95%)18.5 ± 5.4 (16.7;20.3)18.5 ± 4.5 (16.9;20)14.7 ± 2.2 (13.9;15.4)13.6 ± 2.5 (12.8;14.5)14.2 ± 2.4 (13.4;15)14.2 ± 2.7 (13.2;15.1)14.8 ± 1.8 (14.2;15.4)14.8 ± 2.3 (14;15.6)14.9 ± 1.7 (14.3;15.4)14.3 ± 3.1 (13.3;15.4)Punctate keratitis, (yes/no)2/330/325/302/300/358/245/303/291/343/29Inter-treatment and intra-treatment ANOVA (mixed-effect models) not significant*CI* confidence interval, *SD* standard deviationTable 3Confocal data of the study populationBaselineMonth 3Month 6Month 9Month 12LatanoprostTafluprostLatanoprostTafluprostLatanoprostTafluprostLatanoprostTafluprostLatanoprostTafluprostEpithelial density cells/mm^2^ mean ± SD (CI 95%)5800 ± 1136 (5393;6207)6370 ± 928 (6026;6714)6079 ± 677 (5833;6326)6244 ± 939 (5902;6585)6001 ± 610 (5782;6219)6286 ± 947 (5942;6631)5969 ± 677 (5738;6200)6085 ± 892 (5766;6404)5848 ± 726 (5592;6103)6051 ± 886 (5728;6373)Fiber density per frame mean ± SD (CI 95%)4.7 ± 1.7 (4.1;5.2)4.1 ± 1.3 (3.7;4.5)4.8 ± 1.6 (4.3;5.4)4.3 ± 1.5 (3.8;4.9)4.1 ± 1.8 (3.5;4.7)4.8 ± 1.8 (4.1;5.4)4.4 ± 1.7 (3.8;5)4.1 ± 1.5 (3.6;4.7)4.8 ± 1.7 (4.2;5.4)4 ± 1.6 (3.5;4.5)Density of dendritic cells per frame mean ± SD (CI 95%)7.5 ± 9.3 (4.3;10.8)5.9 ± 5.3 (4;7.8)6.7 ± 7.6 (4.1;9.3)5.4 ± 4.9 (3.7;7.2)9.2 ± 9.5 (5.9;12.4)8.7 ± 8.9 (5.5;11.9)8.3 ± 7 (5.9;10.6)7.3 ± 7.1 (4.7;10)9.3 ± 7.6 (6.7;12)7.2 ± 5.3 (5.4;9.1)Endothelial density cells/mm^2^ mean ± SD (CI 95%)2987 ± 1276 (2398;3577)2743 ± 588 (2503;2984)2454 ± 652 (2144;2764)2692 ± 520 (2469;2914)2566 ± 724 (2157;2976)2632 ± 325 (2467;2796)2325 ± 610 (1980;2671)2477 ± 358 (2330;2623)2453 ± 307 (2263;2643)2566 ± 442 (2377;2756)Sub-basal nerve reflectivity, (grade 0/1/2/3/4)2/2/8/20/30/0/14/13/50/1/9/19/61/3/8/16/40/4/9/16/60/0/11/18/30/2/6/17/100/2/10/14/60/3/9/16/70/3/12/11/6Sub-basal nerve tortuosity, (grade 0/1/2/3/4)1/1/11/17/50/1/10/10/110/6/11/7/110/4/9/9/100/2/12/10/110/1/9/15/71/3/8/16/71/5/6/14/60/1/9/17/80/3/7/10/12Sub-basal nerve beading, (yes/no)27/824/830/524/831/424/833/224/8\*33/224/8**\***Presence of activation of the anterior stromal keratocytes, (yes/no)10/2516/1621/1421/1124/1126/626/926/628/727/5Branching pattern, (yes/no)30/527/530/527/530/527/532/327/535/027/5\*\*Inter-treatment and intra-treatment ANOVA (mixed-effect models) not significant*ANOVA* analysis of variance, *CI* confidence interval, *SD* standard deviation\* *p* = 0.05 (inter-treatment *χ* ^2^); \*\* *p* = 0.04 (inter-treatment *χ* ^2^)Fig. 1Confocal images of a patient treated with tafluprost. **a** Sub-basal plexus at baseline. **b** Sub-basal plexus at month 12: no relevant changes of density, length, morphology are shown. **c** Anterior stroma at baseline; no keratocyte activation is present. **d** Anterior stroma at month 12: no changes are shown; keratocyte activation is absentFig. 2Confocal images of a patient treated with latanoprost. **a** Sub-basal plexus at baseline. **b** Anterior stroma at baseline; no keratocyte activation is present. **c** Sub-basal plexus at month 12: disruption of normal nerve structure is shown: branching and beading are present, and nerve is tortuous; density is overall conserved. **d** Anterior stroma at month 12 showing keratocyte activation

During a 1-year interval from treatment beginning, no significant clinical changes were detected, apart from a drop of IOP of 3.6--4.2 mmHg in the two groups (*p* \< 0.001, with no statistically significant difference between treatments; ANOVA).

Confocal microscopy was similar between groups and between time points when analyzed by ANOVA. Yet, subtle changes occurring on the morphology of the cornea were shown at follow-up. All patients without branching pattern of sub-basal nerves at baseline progressively (from 9 to 12 months) developed this pattern when treated with latanoprost, whereas no change occurred at follow-up in subjects treated with tafluprost (*p* = 0.04, month 12). None of the patients without beading at baseline developed beading at the end of the study in tafluprost group, whereas this occurred in 6/8 (75%) patients treated with latanoprost (*p* = 0.05).

Both treatments were associated with an increase of activation of anterior stromal keratocytes at follow-up; the change from baseline was statistically significant 3 months after starting treatment with latanoprost (*p* = 0.02) and 6 months after tafluprost (*p* = 0.04).

A small and not significant increase of dendritic cells density occurred over time, with no difference between treatments.

No significant side effects were detected with any treatment during the study. No significant changes of symptoms were found, as evaluated by COMTOL scale, at follow-up in the two groups. Adherence to treatment was high (96%), and no study discontinuation occurred.

Discussion {#Sec11}
==========

This paper explored the effects of tafluprost and latanoprost on a population of newly diagnosed POAG and OH with normal ocular surface, and the two treatments were found to have the same IOP-lowering effect and clinical tolerability over 1 year of follow-up, thus confirming previous findings \[[@CR25]--[@CR27]\].

One novelty of the present study is that by means of a parallel randomization, prospective and masked design, the two treatments were also compared using confocal microscopy. Using this method, it was shown that a subgroup of otherwise normal subjects at baseline have subclinical corneal patterns (activation of anterior stromal keratocytes, nerve beading and branching). The number of cases with activation of keratocytes increased over time, thus confirming previous findings on the pro-inflammatory effect of prostaglandin analogs (regardless of BAK) \[[@CR23]\]. Of the changes occurring during follow-up on sub-basal nerves, beading and branching were significantly lower in patients receiving tafluprost. Another paper recently compared the corneal confocal findings of the two treatments using a non-randomized design, and showed that tafluprost has a favorable safety profile \[[@CR24]\].

The main difference between the two study treatments is the absence of BAK in tafluprost formulation. BAK has been used for decades on nearly all ophthalmic formulations with an overall low percentage of serious side effects \[[@CR28]\], even if recent studies demonstrated that BAK frequently causes relevant changes on the ocular surface, particularly when inspected by confocal microscopy \[[@CR28]\].

Little is known on the timing of occurrence of ocular surface changes when starting IOP-lowering treatments; in the present study it was shown that keratocyte activation (which was present at baseline in about one-third of eyes) increases immediately after the treatment is started and it tends to increase over time, whereas morphological changes of the nerves are present only after 9--12 months.

Most of the corneal changes found in confocal studies on patients with glaucoma have been attributed to BAK. In particular, BAK has a dose-dependent apoptotic action \[[@CR29]\] which has been shown to disrupt the epithelial barrier of both conjunctiva \[[@CR16], [@CR30]\] and cornea \[[@CR11]\]; at ultrastructural levels, BAK induces a massive reduction of goblet cells \[[@CR16], [@CR30]\] and an anatomical disruption of corneal glycocalyx and microvilli \[[@CR11]\]. In the most severe cases, deeper layers of the ocular surface can also be involved by BAK exposure: conjunctival fibrosis and keratinization have been reported \[[@CR31]\]. Most recently, BAK exposure has been associated also with anterior chamber inflammation \[[@CR32]\].

From the literature, the use of BAK-free treatments is preferable in all cases \[[@CR16], [@CR18], [@CR30], [@CR33], [@CR34]\]. Studies comparing BAK and BAK-free treatments for glaucoma showed the superiority of BAK-free treatments on clinical findings \[[@CR33], [@CR34]\] and, by means of confocal microscopy, conjunctival \[[@CR16], [@CR30]\] and corneal \[[@CR18]\] findings. The non-randomized, cross-sectional paper by Martone et al. \[[@CR18]\] was one of the first to suggest that patients receiving unpreserved treatments for glaucoma have confocal findings more similar to controls than to patients treated with BAK-preserved eye drops.

Regardless of the exposure to BAK, it has been suggested that stromal activation may be facilitated by the pro-inflammatory activity of prostaglandin analogs \[[@CR23]\]. Even if other studies found that activation may be similar for beta-blockers and prostaglandins \[[@CR18], [@CR20]\], the data seem to support the effect of the drug itself on the keratocyte activity.

The beneficial effect of switching from preserved to unpreserved prostaglandin treatment has been explored by a recent study which showed, over a 1-year period, an increase in epithelial and nerve densities, a reduction of keratocyte activation, a reduction of bead-like formations and nerve tortuosity \[[@CR25]\]. Despite these premises, the present study seems to indicate that such findings may not be clinically relevant for newly diagnosed glaucoma patients, without ocular surface disease, receiving low doses of BAK (i.e., monotherapy) for a short period of time. Clinical data and symptoms, in fact, overlapped in the two study groups at all visits. The confocal difference of the two treatments may gain relevance in patients with longer follow-up, with concomitant ocular surface disease, or exposure to higher BAK concentrations due to concomitant use of preserved eye drops. These factors were outside the scope of the study, but these patients will have continued follow-ups to detect possible future clinical and confocal changes.

Readers should be aware that this study reflects the limits of confocal microscopy, i.e., subjectivity and limited repeatability. The area investigated by this device is also very small and may be not representative of the whole cornea. The data are comparable to those available in literature for corneal confocal microscopy of normal patients, with the exception of dendritic cells, which were lower in the present study sample than in literature (although Zhivov et al. \[[@CR35]\]. suggested that dendritic cell density in normal subjects may range from 0 to 64/mm^2^). In general, data on confocal microscopy have a large span of normality, as shown in Table [4](#Tab4){ref-type="table"} \[[@CR35]--[@CR45]\]. Moreover, the discrimination between normal and abnormal findings at confocal investigation is not always univocal; for example, the role played by branching, tortuosity or abnormally high or abnormally low reflectivity is debated \[[@CR16], [@CR18]--[@CR20]\].Table 4Values of normality for confocal findings in naïve subjectsParameterValue of normality, mean ± SDReferencesBasal epithelium (cells/mm^2^ *)*5623 ± 389Martone et al. \[[@CR18]\]5823 ± 602Patel et al. \[[@CR36]\]6333 ± 604Ceresara et al. \[[@CR37]\]8916.7 ± 645.8Hu et al. \[[@CR38]\]8996 ± 1532Eckard et al. \[[@CR39]\]Nerve fibers (fibers/frame)2.9 ± 0.8De Cillà et al. \[[@CR40]\]3.8 ± 0.7Bucher et al. \[[@CR41]\]5.26 ± 1.3Martone et al. \[[@CR18]\]5.85 ± 2.04Ceresara et al. \[[@CR37]\]5.9 ± 0.7Kurbanyan et al. \[[@CR42]\]Nerve fiber density (fibers/mm^2^)31.9 ± 94Hertz et al. \[[@CR43]\]Nerve tortuosity (grade 0--4)1.2 ± 0.39Martone et al. \[[@CR18]\]1.8 ± 0.7Kurbanyan et al. \[[@CR42]\]2.0 ± 0.8De Cillà et al. \[[@CR40]\]2.3 ± 0.6Ceresara et al. \[[@CR37]\]Nerve reflectivity (grade 0--4)2.07 ± 0.9Martone et al. \[[@CR18]\]2.6 ± 0.9De Cillà et al. \[[@CR40]\]Dendritic cell density (cells/mm^2^)34 ± 3Zhivov et al. \[[@CR39]\]34.9 ± 5.7Lin et al. \[[@CR44]\]Endothelial density (cells/mm^2^)2539 ± 338Salvetat et al. \[[@CR45]\]2968 ± 385Ceresara et al. \[[@CR37]\]3105 ± 497Hu et al. \[[@CR38]\]*SD* standard deviation

Due to the paucity of data on confocal microscopy in newly treated glaucoma patients, sample size assumptions were approximate; the inclusion of all available eyes in analysis increased the statistical power of the study but could also limit its validity. Nevertheless, this paper has the merit of a randomized, double-blinded design; the confocal evaluators were blinded to the characteristics of the patients and evaluated images in a blinded fashion.

Conclusion {#Sec12}
==========

In conclusion, the present study found out that the low daily exposure to BAK of patients treated with latanoprost may facilitate the development of confocal changes of the cornea, which occurred less frequently on patients treated with tafluprost. Activation of anterior stromal keratocytes was present at baseline in one-third of cases and increased at follow-up, probably due to the pro-inflammatory activity of prostaglandin analogs. From a clinical viewpoint, the two treatments had similar IOP-lowering effect and tolerability.
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